Pharmacien Hospitalier et Clinicien最新文献

{"title":"Une nouvelle méthode pédagogique pour les étudiants en pharmacie clinique et pour les pharmaciens : le projet « V-Idées-Oh » sur des thèmes pédiatriques","authors":"Charlotte Lescuyer , Clarisse Peltier , Eva Fryde , Virginie Lasserre , Olivier Bourdon , Anne Rouault , Sonia Prot-Labarthe","doi":"10.1016/j.phclin.2020.12.001","DOIUrl":"10.1016/j.phclin.2020.12.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Les enfants ne sont pas des « adultes miniatures ». Les pharmaciens et les étudiants en pharmacie doivent y être sensibilisés pour développer des compétences en pharmacie clinique pédiatrique.</p></div><div><h3>Matériel et méthodes</h3><p>Dans le contexte d’un diplôme universitaire de pharmacie clinique pédiatrique et de 6 e année de filière officine, nous avons développé une nouvelle méthode pédagogique de type classe inversée. Ce projet, initié en 2017 par deux étudiantes en pharmacie, les membres de la cellule TICE et deux pharmaciens et enseignants spécialisés en pédiatrie a touché 30 pharmaciens et internes et 86 étudiants. Les thèmes choisis étaient « Le médicament pédiatrique » et « La fièvre chez l’enfant ».</p></div><div><h3>Résultats</h3><p>Au total, 4 vidéos ont été créées. Après visionnage, les participants devaient réaliser une fiche synthèse puis travailler sur des cas cliniques avec les intervenants des vidéos. Les participants ont été satisfaits par ce nouvel outil V-Idée-Oh (96 %), par la vision de la vidéo avant le cours (92 %). Concernant la préparation de la fiche, 81 % ont été satisfaits par ce travail en amont.</p></div><div><h3>Discussion</h3><p>Nous avons testé cette année une nouvelle méthode pédagogique sur deux thèmes de base. Grâce aux commentaires recueillis, nous allons raccourcir la préparation des cours cas et nous élargirons cette méthode pour d’autres thèmes pour les prochaines sessions.</p></div><div><h3>Conclusion</h3><p>Cette nouvelle méthode pédagogique est attractive pour les étudiants et pour les enseignants. Cet article décrit ses modalités pratiques pour être transposable dans d’autres universités et sur d’autres thématiques.</p></div><div><h3>Introduction</h3><p>Children are not “miniature adults”. Pharmacists and pharmacy students need to be sensitized to this fact in order to develop pediatric clinical pharmacy skills.</p></div><div><h3>Materiel and methods</h3><p>In the context of a “Pediatric Clinical Pharmacy” teaching course and for the 6th and last community pharmacy university year, we developed a new concept of reverse teaching skills. In 2017, a multidisciplinary project involving two pharmacy students, the information and communication technology unit, and two pharmacists and teachers specialized in pediatrics concerned 30 pharmacy residents and pharmacists and 86 students. The topics chosen were “Pediatric medication” and “Fever in children”.</p></div><div><h3>Results</h3><p>Four videos were implemented. The participants had to summarize the important notions and prepare clinical cases. The participants were satisfied by this new V-Idée-Oh tool (96%), by the vision of the video before the course (92%). About the summary, 81% were satisfied by this upstream work.</p></div><div><h3>Discussion</h3><p>This year we tested a new teaching method on two basic themes. Thanks to the comments collected, we will shorten the summary exchange and we will enlarge this method for","PeriodicalId":38762,"journal":{"name":"Pharmacien Hospitalier et Clinicien","volume":"56 2","pages":"Pages 177-184"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.phclin.2020.12.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41837781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remerciements aux experts 2020","authors":"","doi":"10.1016/S2211-1042(21)00030-8","DOIUrl":"https://doi.org/10.1016/S2211-1042(21)00030-8","url":null,"abstract":"","PeriodicalId":38762,"journal":{"name":"Pharmacien Hospitalier et Clinicien","volume":"56 1","pages":"Page 115"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2211-1042(21)00030-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137142059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"L’évolution intelligente","authors":"M. Juste","doi":"10.1016/j.phclin.2021.01.004","DOIUrl":"10.1016/j.phclin.2021.01.004","url":null,"abstract":"","PeriodicalId":38762,"journal":{"name":"Pharmacien Hospitalier et Clinicien","volume":"56 1","pages":"Pages 1-2"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211104221000060/pdfft?md5=c194aed15964c7940dcbaac66295deb9&pid=1-s2.0-S2211104221000060-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44952180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Troubles neurologiques sous Daptomycine en réanimation : effet indésirable ou mésusage ? Cas clinique","authors":"A. Durand , S. Cayeux , A. Adehossi , J. Richecoeur , B. Schmit","doi":"10.1016/j.phclin.2020.08.005","DOIUrl":"10.1016/j.phclin.2020.08.005","url":null,"abstract":"","PeriodicalId":38762,"journal":{"name":"Pharmacien Hospitalier et Clinicien","volume":"56 1","pages":"Pages 87-90"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211104220301168/pdfft?md5=fb3a55c3cfa97c8fd2e50a604d981f6d&pid=1-s2.0-S2211104220301168-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47041360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Évaluation du circuit des dispositifs médicaux stériles et implantables au Centre Hospitalier de Laval : cartographie des risques et mise en place d’actions correctives","authors":"Pauline Rault ,&nbsp;Nathalie Naturel ,&nbsp;Elisabeth Bedouet ,&nbsp;Céline-Marie Delafontaine ,&nbsp;Catherine Gilmas ,&nbsp;Liliane Zbierski ,&nbsp;Françoise Lecomte","doi":"10.1016/j.phclin.2020.10.002","DOIUrl":"10.1016/j.phclin.2020.10.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Le circuit des dispositifs médicaux stériles et implantables (DMS/DMI) est complexe et peut entraîner des évènements indésirables associés aux soins. L’objectif de ce travail est d’évaluer puis d’optimiser la sécurisation de ce circuit dans notre établissement.</p></div><div><h3>Matériels et méthodes</h3><p>La grille InterDiag DMS® V2.0 de l’Agence Nationale d’Appui à la Performance a été choisie. Elle comprend deux modules évaluant le circuit des DMS, des DMI et les DMS utilisés dans cinq pratiques de soins. Les audits des unités de soins (US) et de la pharmacie (PUI) ont été réalisés entre novembre 2019 et février 2020.</p></div><div><h3>Résultats</h3><p>Dix-neuf US dont la PUI ont été auditées. Les taux de maîtrise globaux des différents items évoluent entre 62 et 74 %. Les étapes ayant les taux de maîtrise les plus faibles sont la demande (PUI : 50 %), le transport (PUI : 46 %), le stockage (US : 44 %) et l’évaluation de la traçabilité des DMI (PUI : 45 %). Parmi les 45 actions de sécurisation formulées, 16 ont été mises en place comme la réalisation d’audits sur la traçabilité des DMI.</p></div><div><h3>Dicussion et conclusion</h3><p>La cartographie effectuée de façon multidisciplinaire montre une bonne maîtrise globale du circuit. Les étapes les plus à risques identifiées sont en cours de sécurisation. Le plan d’action formulé devra être suivi et actualisé chaque année.</p></div><div><h3>Introduction</h3><p>The circuit of sterile and implantable medical devices (MD) is complex and can lead to adverse events associated with care. The objective of this work is to assess and then optimize the security of this circuit in our establishment.</p></div><div><h3>Materials and methods</h3><p>The InterDiag ® V2.0 grid from the Agence Nationale d’Appui à la Performance was chosen. It includes two modules evaluating the circuit of sterile MD, implantable MD and sterile MD used in five health care practices. The care unit (CU) and pharmacy audits were carried out between November 2019 and February 2020.</p></div><div><h3>Results</h3><p>Nineteen CU including the pharmacy were audited. The overall mastery rates for the various items vary between 62 and 74%. The stages with the lowest control rates are demand (pharmacy: 50%), transport (pharmacy: 46%), storage (CU: 44%) and evaluation of the traceability of implantable MD (pharmacy: 45%). Among the 45 security actions formulated, 16 have been implemented as audits of the traceability of implantable MD.</p></div><div><h3>Discussion and conclusion</h3><p>The cartography carried out in a multidisciplinary way shows a good control of the circuit. The most risky stages identified are in the process of being secured. The formulated action plan will have to be monitored and updated every year.</p></div>","PeriodicalId":38762,"journal":{"name":"Pharmacien Hospitalier et Clinicien","volume":"56 1","pages":"Pages 75-83"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211104220301375/pdfft?md5=ccbd7ce14f8c35cbf4c46e978f5b4b7b&pid=1-s2.0-S2211104220301375-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46124402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparation, validation and user-testing of patient information leaflet on cancer","authors":"U.P. Nandakumar ,&nbsp;J.J. Joel ,&nbsp;J. Shetty ,&nbsp;C.S. Shastry ,&nbsp;C.H. Krishna Bhat","doi":"10.1016/j.phclin.2020.07.012","DOIUrl":"10.1016/j.phclin.2020.07.012","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;p&gt;Patient information leaflet contains specific information regarding the medical conditions, medications as well as the lifestyle modifications required to be followed by the patients. The information collected for the leaflet should be in the simplest form possible so that it can be easily interpreted by the targeted population.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;The present study aims to develop and validate patient information leaflet for cancer patients.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;p&gt;The information for the leaflet was gathered from various primary, secondary and tertiary resources. The content of the leaflet was validated by 10 members including general physicians, medical oncologists, academic pharmacists and clinical pharmacists. Readability of the patient information leaflets was assessed using Flesch Reading Ease test, Flesch-Kincaid Grade Level test and user readability method. User opinion on the content, layout and design was also obtained from the enrolled patients.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results and discussion&lt;/h3&gt;&lt;p&gt;The FRE and FK-GL scores of English version of patient information leaflet were 61.2 and 7.9 respectively. The overall user readability score of English, Kannada and Malayalam versions of PIL improved significantly from a pre-test score of 41.80&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;23.18 to a post-test score of 70.40&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;23.03. Ninety percent of the total patients enrolled in the study recorded good opinion about the leaflet in terms of its content, layout and design.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;Patient information leaflet based education had a significant impact in improving the knowledge level of cancer patients.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;p&gt;La brochure d’information destinée aux patients contient des informations spécifiques concernant les conditions médicales, les médicaments ainsi que les modifications du mode de vie que doivent suivre les patients. Les informations recueillies pour la brochure doivent être présentées sous la forme la plus simple possible afin qu’elles puissent être facilement interprétées par la population ciblée.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;p&gt;La présente étude vise à développer et à valider la brochure d’information destinée aux patients atteints de cancer.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériels et méthodes&lt;/h3&gt;&lt;p&gt;Les informations contenues dans la brochure ont été recueillies auprès de diverses ressources primaires, secondaires et tertiaires. Le contenu de la brochure a été validé par 10 membres, dont des médecins généralistes, des oncologues médicaux, des pharmaciens universitaires et des pharmaciens cliniciens. La lisibilité des brochures d’information destinées aux patients a été évaluée à l’aide du test Flesch Reading Ease, du test Flesch-Kincaid Grade Level et de la méthode de lisibilité par l’utilisateur. L’opinion des utilisateurs sur le contenu, la mise en page et la conception a également été obtenue auprès des patients inscrits.&lt;/p&gt;&lt;","PeriodicalId":38762,"journal":{"name":"Pharmacien Hospitalier et Clinicien","volume":"56 1","pages":"Pages 12-17"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.phclin.2020.07.012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44419751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the efficacy of BCG vaccination in the protection from COVID-19 in European countries?","authors":"K. Ghazvini ,&nbsp;M. Keikha","doi":"10.1016/j.phclin.2020.08.001","DOIUrl":"10.1016/j.phclin.2020.08.001","url":null,"abstract":"","PeriodicalId":38762,"journal":{"name":"Pharmacien Hospitalier et Clinicien","volume":"56 1","pages":"Pages 84-86"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.phclin.2020.08.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79410490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyse des interventions pharmaceutiques selon les critères de risque liés à l’utilisation du ténofovir chez les patients VIH positifs à Abidjan","authors":"Thierry Alexis Boua Kamenan ,&nbsp;Dean Wilfried Kader Kohou ,&nbsp;Danho Pascal Abrogoua","doi":"10.1016/j.phclin.2020.09.002","DOIUrl":"10.1016/j.phclin.2020.09.002","url":null,"abstract":"<div><h3>Introduction</h3><p>L’utilisation du ténofovir chez les patients atteints du VIH n’est pas sans risque. L’objectif de cette étude était d’analyser les interventions pharmaceutiques formulées au cours du suivi des personnes vivant avec le VIH sous ténofovir en fonction des critères de risque.</p></div><div><h3>Matériel et méthodes</h3><p>Une étude transversale à visée descriptive a été menée sur une période de six mois au CHU de Cocody-Abidjan (Côte d’Ivoire). Elle concernait les patients VIH positifs sous ténofovir suivis en ambulatoire et ayant au moins un critère de risque lié à utilisation de ce médicament.</p></div><div><h3>Résultats</h3><p>Au total 98 critères de risque ont été identifiés chez 59 patients soit 1,7 critères de risque par patient. Cent quinze interventions pharmaceutiques ont été formulées correspondant aux problèmes pharmacothérapeutiques détectés. Toutes ces interventions pharmaceutiques ont été acceptées par les prescripteurs.</p></div><div><h3>Discussion</h3><p>Le suivi biologique doit être approfondi en dehors du bilan de suivi de routine chez les patients VIH positifs sous ténofovir présentant au moins critère de risque.</p></div><div><h3>Conclusion</h3><p>L’implication du pharmacien en réalisant des interventions pharmaceutiques améliore la prise en charge des patients sous traitement ARV.</p></div><div><h3>Introduction</h3><p>Use of tenofovir during antiretroviral therapy causes risks in patients. The aim of this study was to analyse pharmaceutical interventions formulated during follow-up of people living with HIV treated by tenofovir according to risk criteria.</p></div><div><h3>Material and methods</h3><p>A cross-sectional descriptive study was conducted over a period of six months at the Cocody-Abidjan University Hospital (Côte d’Ivoire). It concerned positive HIV outpatients treated with tenofovir and having at least one risk criterion linked on use this drug.</p></div><div><h3>Results</h3><p>A total 98 risk of criteria were identified in 59 patients, i.e. 1.7 risk criteria per patient. One hundred fifteen pharmaceutical interventions were formulated against pharmacotherapeutic problems detected. All of proposed pharmaceutical interventions (100%) were accepted by prescribers.</p></div><div><h3>Discussion</h3><p>Biological monitoring must be deeped in as soon as one risk criterion exist outside routine monitoring assessment in positive HIV patients treated by tenofovir.</p></div><div><h3>Conclusion</h3><p>Involvement of pharmacist by carrying out pharmaceutical interventions improves management of patients on antiretroviral treatment.</p></div>","PeriodicalId":38762,"journal":{"name":"Pharmacien Hospitalier et Clinicien","volume":"56 1","pages":"Pages 36-43"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211104220301193/pdfft?md5=985425efe020cb173ee28e4f35acb7fe&pid=1-s2.0-S2211104220301193-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48447464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Annonces de congrès","authors":"","doi":"10.1016/j.phclin.2021.01.003","DOIUrl":"https://doi.org/10.1016/j.phclin.2021.01.003","url":null,"abstract":"","PeriodicalId":38762,"journal":{"name":"Pharmacien Hospitalier et Clinicien","volume":"56 1","pages":"Page 114"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.phclin.2021.01.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137142058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Curcumin be used as a therapeutic agent to eradicate Helicobacter pylori infection? Evidence from human clinical trials","authors":"K. Ghazvini ,&nbsp;M. Keikha","doi":"10.1016/j.phclin.2020.09.006","DOIUrl":"10.1016/j.phclin.2020.09.006","url":null,"abstract":"","PeriodicalId":38762,"journal":{"name":"Pharmacien Hospitalier et Clinicien","volume":"56 1","pages":"Pages 93-97"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2211104220301351/pdfft?md5=487cf2a26a85b370c44fc1fd0958bc11&pid=1-s2.0-S2211104220301351-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44706387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}